Introduction: Despite recent prognostic improvements, mantle cell lymphoma (MCL) remains incurable. Bruton tyrosine kinase (BTK) is a key receptor in B-cell tumorigenesis, and the benefits of the first BTK inhibitor, ibrutinib, are becoming clear in MCL. However, off-target activities, which contribute to ibrutinib-related adverse events, suggest potential for further improvement of this drug class. Areas covered: The authors systematically interrogated ClinicalTrials.gov for trials containing keywords for BTK and MCL. Published literature for new and emerging BTK inhibitors being investigated in MCL was then identified (PubMed and Embase),
A c c e p t e d M a n u s c r i p t Indeed, data from patients with chronic lymphocytic leukemia (CLL) taking ibrutinib show that AEs are a common reason for treatment discontinuation [24, 25] . The state of emerging BTK inhibitors and their implications for the future treatment of B-cell malignancies has recently been reviewed [26] . Here we focus on new and emerging BTK inhibitors that are specifically under investigation in patients with MCL and discuss their potential placement in MCL treatment guidelines.
Materials and methods
Searches were conducted on 15 August 2017 in ClinicalTrials.gov to identify trials with fields containing key terms for BTK inhibitors (BTK OR Bruton OR Bruton's OR Brutons) AND MCL (MCL OR mantle). Filters were applied to exclude studies that had been terminated or withdrawn. It is possible that clinical trials not specifically mentioning MCL in either the 'condition' or 'submitted keywords' fields in ClinicalTrials.gov may include patients with MCL as part of a broader clinical trial population. However, for the purpose of focusing this review, we considered an absence of MCL search terms to indicate a lack of intent by the investigator and/or manufacturer to move forward into MCL with their molecule. Searches were performed in PubMed (for full papers) and Embase (for conference abstracts) on 21 September 2017 to identify primary research articles with information on new and emerging BTK inhibitor molecules identified from the ClinicalTrials.gov searches.
The 'hits' from these searches were screened to exclude those with irrelevant study topics and study types (e.g. reviews).
New and emerging BTK inhibitors in MCL
In total, 36 trials were identified on ClinicalTrials.gov that included search terms for BTK inhibitors and MCL. Of these, five were excluded because search terms were present in the introductory text but were not the focus of the clinical trial, and 21 were excluded because they were investigating ibrutinib as the only BTK inhibitor. The Table 1 . Data identified from the targeted literature searches for each of these molecules are A c c e p t e d M a n u s c r i p t summarized below, with the exception of CT-1530 for which no published articles (full papers or conference abstracts) were identified.
Acalabrutinib (ACP-196)
Acalabrutinib inhibits BTK by covalently and irreversibly binding to Cys-481. The IC 50 value (concentration where the response is reduced by half) for acalabrutinib against purified BTK is 5.1 nM compared with 1.5 nM for ibrutinib [27] . In cellular assays, EC 50 values (concentration that gives the half-maximal response) for acalabrutinib and ibrutinib for inhibition of B-cell receptor (BCR)-induced CD69 expression are 2.9 nM and 0.58 nM, respectively, in peripheral blood mononuclear cells, with comparable results in human whole blood (9.2 nM and 5.8 nM, respectively) [27] . The degree of inhibition of BCR-induced responses (BTK, S6 and ERK phosphorylation) is also similar for these molecules in primary CLL cells [28] .
In mice, the ED 50 value (dose where the measured effect occurs in at least 50% of samples) for inhibition of CD69 expression in splenocytes was 1.3 mg/kg for acalabrutinib and 2.9 mg/kg for ibrutinib [27] . Pre-clinical anti-tumor effects have been demonstrated for acalabrutinib in terms of reduced cell viability in large B-cell lymphoma cell lines [29], induction of apoptosis in primary CLL cells [28, 30] and improved outcomes in a canine B-cell NHL model and two mouse CLL models [31, 32] . In healthy volunteers acalabrutinib is rapidly absorbed (T max [time to maximum plasma concentration of drug] of 0.5-1.0 hours), has a short half-life (T ½ [time required for elimination of 50% of drug from plasma] of 0.88-2.1 hours), and reaches full target occupancy with a single 100 mg dose [27] . Robust response rates have been reported with acalabrutinib in a phase 1/2 clinical trial in both relapsed or refractory and untreated patients with CLL (NCT02029443) [33, 34] . In this trial, the highest rate of BTK occupancy (98%) was observed with twice-daily dosing [34] .
Acalabrutinib has fewer off-target effects than ibrutinib. In a panel of 395 non-mutant kinases, 1.5% were inhibited by at least 65% by 1 μM acalabrutinib, compared with 8.9% for 1 μM ibrutinib [27] . Acalabrutinib also has much lower activity than ibrutinib against kinases with a cysteine in the same position as BTK (TEC family   kinases [ITK, TXK, BMX, TEC] [27] . Ibrutinib has been shown to also inhibit SRC, LCK and ITK far more potently than acalabrutinib in healthy T cells [28] .
No cases of atrial fibrillation have been observed so far in the phase 1/2 clinical trial of acalabrutinib in the 61 patients with relapsed or refractory CLL, after a median follow-up period of 14.3 months (NCT02029443) [33] . Although rates of atrial fibrillation in this study would be influenced by the exclusion of patients with significant cardiovascular disease and electrocardiogram abnormalities, significant cardiovascular disease was also an exclusion criterion in an ibrutinib trial where cases of atrial fibrillation occurred in 10 out of 195 patients (5%) with relapsed or refractory CLL after a median follow-up of 9.4 months, of which six cases (3%) were grade 3 or higher (NCT01578707) [21] . In another trial in patients with relapsed or refractory CLL, where the presence of electrocardiogram abnormalities was an exclusion criterion, atrial fibrillation was reported as a serious AE in 3 (4%) of 85 patients (median follow-up: 20.9 months) (NCT01105247) [35] . In the phase 1/2 trial of acalabrutinib in CLL there have been no cases of atrial fibrillation with acalabrutinib treatment in the 72 patients with treatment-naïve CLL, at a median follow-up of 11 months (NCT02029443) [34] . In a trial of 136 patients with treatment-naïve CLL receiving ibrutinib, 8 (6%) developed atrial fibrillation (1% were grade 3 or higher) at a median follow-up of 17.4 months [36] . Both studies excluded patients with significant cardiovascular disease [34, 36] .
No cases of major hemorrhage have been reported in the phase 1/2 clinical trial of acalabrutinib in patients with relapsed or refractory (n = 61) or treatment naïve CLL (n = 72) (NCT02029443) [33, 34] , with the exception of a single grade 3 gastric ulcer bleed due to aspirin use [34] . Clinical trials of ibrutinib have reported grade 3 or Acalabrutinib appears less likely to aggravate or precipitate AEs that lead to ibrutinib discontinuation [22, 23] .
Headache has been more frequent in acalabrutinib CLL trials (42-43%) [33, 34] than in ibrutinib CLL trials (14-18%) [21, 35] . All cases of headache reported for acalabrutinib have been grade 1 or 2, have occurred early in treatment and have generally resolved over time, and have not caused any patients to discontinue.
Conversely, diarrhea and fatigue have been more common in ibrutinib CLL trials (42-49% and 28-32%, respectively [21, 35, 36] ) than in acalabrutinib CLL trials (35-39% and <15-21%, respectively [33, 34] ). However, acalabrutinib and ibrutinib have not been directly compared in any head-to-head clinical trials. Such data are necessary to eliminate variations in study design between acalabrutinib and ibrutinib trials that may impact on observed differences in the rates of specific AEs.
In October 2017, the Food and Drug Administration (FDA) approved acalabrutinib for use as a single agent in patients with relapsed or refractory MCL, based on the positive results of a phase 2 study (NCT02213926: Table 1 ). In this trial, the overall response rate (ORR) for acalabrutinib 100 mg given twice daily to patients with MCL (N = 124) was 81% (complete response in 40%) at a median follow-up of 15.2 months (median duration of response, progression-free survival and overall survival were not reached) [37] . The ORR for ibrutinib 560 mg once daily in the pivotal trial that led to its approval in patients with relapsed or refractory MCL (N = 111) was 68% (complete response in 27%) at a median follow-up of 15.3 months (NCT01236391)
[18], although patients in this trial population were more heavily pre-treated and a lower proportion (14%) had low-risk simplified Mantle Cell Lymphoma International Prognostic Index scores than in the acalabrutinib MCL trial (39%) [37] .
The most common (≥ 20%) AEs in the acalabrutinib MCL trial were headache (38%), diarrhea (31%), fatigue (27%) and myalgia (21%) [37] . There were no cases of atrial hemorrhage in one patient with a history of a GI ulcer) [37] . In the ibrutinib MCL trial, the most common (≥ 20%) AEs were diarrhea (50%), fatigue (41%), nausea (31%), peripheral edema (28%), dyspnea (27%), constipation (25%), upperrespiratory tract infection (23%) and decreased appetite (21%) [18] . Serious AEs of atrial fibrillation occurred in five patients (5%) and grade 3 bleeding events also occurred in five (5%) patients [18] .
Acalabrutinib is also being investigated in combination with BR in patients with untreated MCL (NCT02717624 [phase 1] and NCT02972840 [phase 3]; Table 1 ), and in more 'experimental' combinations with the phosphoinositide 3-kinase inhibitor ACP-319 (NCT02328014 [phase 1/2]) and the immune 'checkpoint' inhibitor pembrolizumab (NCT02362035).
Zanubrutinib (BGB-3111)
Zanubrutinib is an irreversible BTK inhibitor [38, 39] . The binding site for this molecule has not (to our knowledge) been made publicly available. Zanubrutinib inhibits BTK activity at unspecified nanomolar concentrations in biochemical assays and inhibits BCR-induced responses (BTK auto-phosphorylation and downstream PLCɣ2 signalling) in several MCL and diffuse large B-cell lymphoma cell lines [40] .
Zanubrutinib also has anti-proliferative effects and induces apoptosis in MCL cell lines, and has similar anti-tumor activity to ibrutinib in a subcutaneous MCL xenograft mouse model, but at a much lower dosage (2.5 mg/kg twice daily) versus ibrutinib (50 mg/kg once daily) [40, 41] .
In a phase 1 study in patients with relapsed or refractory B-cell malignancies, bioavailability of zanubrutinib 80 mg once daily was similar to that for ibrutinib 560 mg once daily [38] . In addition, a mean 24-hour BTK occupancy of 98.6% was reported with zanubrutinib 40 mg once daily, compared with greater than 90% occupancy reported for acalabrutinib 200 mg once daily [42] , which was itself reported as having better target coverage than ibrutinib 420 mg once daily. Of six patients in the phase 1 study who have MCL, four have had an objective response (one complete response) after a median follow-up of 227 days [38] .
A c c e p t e d M a n u s c r i p t Zanubrutinib is reported as having greater selectivity than ibrutinib for BTK versus EGFR, FGR, FRK, HER2, HER4, ITK, JAK3, LCK, BLK and TEC, although specific values were not able to be identified from the literature [38, 40] . No drugrelated serious AEs or AEs leading to discontinuation have been observed in the phase 1 trial (N=25) of zanubrutinib in patients with relapsed or refractory B-cell malignancies, and no cases of grade 3 or 4 bleeding or of atrial fibrillation (including in four patients with a history of atrial fibrillation) have been reported [38] .
Taken together, the above data indicate that zanubrutinib is a potent inhibitor of BTK, with potentially better selectivity, bioavailability and target coverage than ibrutinib.
There is one ongoing phase 2 trial of zanubrutinib in patients with relapsed or refractory MCL (NCT03206970; Table 1 ), but no data are yet available. Although not the focus of the clinical trial searches, it is worth noting that a phase 3 trial comparing zanubrutinib to ibrutinib in patients with Waldenstrom Macroglobulinemia is ongoing (NCT03053440), and should provide useful information regarding the relative toxicity of these two drugs.
M7583
M7583 is an irreversible inhibitor of BTK. Where this molecule binds to BTK is not clearly described in the literature. Nevertheless, it has high potency, with an IC 50 of 1.48 nM against purified BTK [43] . M7583 was found to inhibit six (2.2%) of a panel of 270 kinases by more than 50% (ZAP-70, BLK, BMX, TXK, ITK and SKG) at a concentration of 1μM [43] , which is comparable to the level of enhanced selectivity exhibited for acalabrutinib versus ibrutinib (inhibition [≥ 65%] of 1.5% vs 8.9 of 395 kinases, respectively, at a concentration of 1μM) [27] .
M7583 is reported as having relatively low bioavailability of 16%, a short half-life of 45 minutes, and a high (but unspecified) degree of BTK occupancy after dosing in mice, and is currently being investigated in patients with relapsed or refractory B-cell malignancies in a phase 1/2 trial (NCT02825836 ; Table 1 ). At the time of reporting, preliminary data from three subjects (one with MCL) enrolled in this trial showed that all had an objective response, or stable disease and a relevant clinical benefit [44] .
A c c e p t e d M a n u s c r i p t
SNS-062
SNS-062 is a non-covalent (reversible) BTK inhibitor. The IC 50 value for SNS-062 against purified BTK is 2.9 nM [45] , and this molecule has been shown to inhibit BTK auto-phosphorylation in human whole blood and in mice [45] . In biochemical assays, SNS-062 exhibited binding to eight kinases at a concentration of less than 25 nM, including BTK (0.3 nM) and the TEC kinase family member, ITK (2.2 nM) [45] .
SNS-062 has been shown to decrease B-cell activation markers, viability and stromal cell protection in primary CLL cells [46] . Unlike ibrutinib and acalabrutinib, SNS-062 maintains its potent inhibitory activity against both wild-type BTK and cysteine 481 to serine (C481S)-mutated BTK [45, 46] . SNS-062 is reported as having good oral bioavailability and tolerability in rats and dogs, with higher continuous drug levels and exposures than ibrutinib [45] . AEs reported in a phase 1 trial of SNS-062 conducted in healthy volunteers included headache in 5 patients (25%) and nausea, bronchitis, fatigue, orthostatic hypotension, and supraventricular tachycardia in one patient (4%) each [47] .There is one ongoing phase 1/2 clinical trial for SNS-062 in patients with B-lymphoid malignancies (NCT03037645 ; Table 1 ). No data are yet available for this trial.
ARQ-531
ARQ-531 is a reversible inhibitor of BTK and has an IC 50 value of 0.85 nM [48] .
Treatment with ARQ-531 inhibits BCR-induced responses (BTK, AKT and ERK phosphorylation) in primary CLL cells [49] . However, this molecule demonstrates off-target activity against a number of other kinases, including the majority of SRC and TEC family kinases [49] . ARQ-531 exhibits better activity than ibrutinib in terms of reducing primary CLL cell viability and increasing survival times in a TCL1 mouse model of leukemia [49] . In addition, ARQ-531 has similar IC 50 values against both wild-type and C481S-mutated BTK [49] . Treatment with ARQ-531 also reduces the viability of primary CLL cells from patients with C481S-mutated BTK [49] , and has anti-proliferative activity against ibrutinib-resistant SUDHL-4 cells in tissue culture and a xenograft mouse model [48] .
In a single oral dose study conducted in monkeys, the bioavailability of 10 mg/kg ARQ-531 was 72.4% [49] . This molecule is being investigated in a phase 1 trial in A c c e p t e d M a n u s c r i p t patients with hematological malignancies (NCT03162536 ; Table 1 ). No published data for this clinical trial were identified from our literature searches.
ONO/GS-4059
Although not mentioned in relation to MCL in ClinicalTrials.gov (and thus not reviewed in detail here), the irreversible BTK inhibitor ONO/GS-4059 should also be mentioned. This molecule had significant activity in patients with relapsed/refractory B-cell malignancies in a phase 1 trial, including in a sub-set of 12 patients with MCL, of whom 11 responded to treatment (median treatment duration: 40 weeks) [50] .
Further details of this molecule, which also has greater selectivity compared with ibrutinib, are well summarized in the recent review by Wu and colleagues [26]. 
BTK inhibitor pipeline in the context of MCL guidelines

Conclusion
New and emerging BTK inhibitors have the potential to further optimize the treatment of patients with this promising class of molecules. Placement of these drugs among MCL treatment guidelines is likely to evolve substantially over the coming years, as A c c e p t e d M a n u s c r i p t safety and efficacy data from a number of ongoing trials exploring their potential synergy with other drugs, particularly targeted therapies, become available.
Expert commentary
The available evidence indicates that covalent, irreversible BTK inhibitors being investigated in patients with MCL (acalabrutinib, BGB-311 and M7583) may have similar potency to ibrutinib, but with reduced off-target activity that could translate into improved safety and tolerability. Favorable clinical data for acalabrutinib raise the possibility that efficacy may also be enhanced, possibly as a result of more complete and continuous inhibition of BTK due to its pharmacokinetic and pharmacodynamic properties, although no head-to-head data are available and therefore differences in the trial populations used may be a factor. The potential for improved safety and tolerability seems less likely to apply to non-covalent, reversible BTK inhibitors being investigated in MCL (SNS-062 and ARQ-531), because these molecules appear to have significant off-target activity against kinases that may be responsible for AEs associated with ibrutinib, including bleeding and atrial fibrillation [58] [59] [60] [61] . Where the strengths of these molecules may lie is in their activity against C481S-mutated BTK, an established mechanism of secondary (acquired) ibrutinib resistance in MCL, although alternative mechanisms unrelated to the BTK pathway (e.g. downstream PIK3-AKT pathway activation) may provide a greater contribution to primary ibrutinib resistance in these patients [62] . The relative clinical importance of different ibrutinib resistance mutations in MCL remains an active area of investigation. Other advantages may well exist for these molecules that cannot be easily deduced from the currently available literature. Indeed, most of the available literature on new and emerging BTK inhibitors pertains to acalabrutinib.
In any of the MCL treatment settings being investigated for ibrutinib, a BTK inhibitor with similar (or better) efficacy but an improved safety and tolerability profile would represent an attractive alternative, providing (at the very least) an avenue to continue BTK inhibitor therapy in patients who would otherwise discontinue. AEs associated with ibrutinib are a major impediment to achieving the best possible outcomes with this breakthrough class of molecules. This is particularly relevant to MCL, where the median age at onset is 68 years, meaning that the majority of patients will require less aggressive induction therapy. Both ibrutinib and acalabrutinib are being investigated A c c e p t e d M a n u s c r i p t in phase 3 trials in this setting in combination with BR (NCT01776840 and NCT02972840, respectively; Figure 1 ).
Finally, it should be noted that, while data from single arm trials do indicate a more favourable AE profile for acalabrutinib versus ibrutinib, no head-to-head data are yet available. Such data are important for addressing the potential effects of study design variation on observed safety profiles, such as exclusion criteria that could influence rates of bleeding and atrial fibrillation with these drugs. To this end, an ongoing phase 3 head-to-head study of ibrutinib and acalabrutinib in patients with relapsed or refractory CLL (NCT02477696) will be particularly useful in cementing differences in the safety profiles of these drugs that have been hinted at in trials conducted to date.
Five-year view
It is expected that several key trials in MCL will read out in the next year or two. This will include the use of BTK inhibition with BR versus BR alone (NCT01776840). If positive, then BTK inhibition will be included in the upfront treatment of patients with MCL. The next logical question is whether the chemotherapy (bendamustine) component is required, or whether the addition of a CD20 antibody (rituximab) is sufficient. Early data from the MD Anderson Cancer Centre show a response rate of 100% has been achieved when ibrutinib plus rituximab is used upfront. A UK trial comparing rituximab-CHEMO (Bendamustine OR CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone]) with rituximab-ibrutinib as front-line therapy for elderly patients is ongoing. If positive, chemotherapy-free treatment will become the new standard of care for elderly patients. In the relapse setting, BTK inhibition has been combined with BCL-2 inhibition in a phase 2 trial (NCT02471391), and a randomized phase 3 trial has started as well (NCT03112174).
If positive, the BTK inhibitor plus BCL-2 inhibitor combination will be a new standard in relapsed or refractory MCL. It could then also be possible to have an upfront chemotherapy free regimen in elderly patients that includes BTK inhibition plus BCL-2 inhibition plus anti-CD20 monoclonal antibody therapy. While no such trials are currently underway, one might expect their initiation in the next few years.
The field is truly exciting with novel agents having significant activity. • Trials of acalabrutinib, which has now been approved in the USA as secondline treatment for MCL, suggest that both safety and efficacy could be enhanced versus ibrutinib, although no head-to-head data are yet available.
• Placement of BTK inhibitors in MCL treatment guidelines will likely evolve substantially over the coming years, as the results of trials exploring earlier use of these drugs (e.g. as less-aggressive induction therapy), and their potential synergy with other targeted therapies, become available.
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